Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15616809 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL17480751 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL15130583 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL13434053 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL16329221 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL14330842 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL16075605 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL13497925 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL13449873 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL31395477 | 1.00 | MGMT (0.41) | MGMTABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362478-B | De-sulfating heparin carrier and preparation method and application thereof | 海南大学 | 2024-07-26 | — | — | CN | claimed |
| CN-117964917-A | Melittin hydrogel and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-05-03 | — | — | CN | claimed |
| CN-115626916-B | Pomalidomide derivative as well as preparation method and application thereof | 河南科技大学第一附属医院 | 2024-01-30 | — | — | CN | claimed |
| CN-115636815-B | Preparation method and application of pomalidomide connected urea compound | 新乡学院 | 2023-10-27 | — | — | CN | claimed |
| CN-116262773-A | Method for artificially synthesizing sequence-controllable polysaccharide | 中国科学院深圳先进技术研究院 | 2023-06-16 | — | — | CN | claimed |
| CN-115636815-A | Preparation method and application of novel pomalidomide-linked urea compound | 新乡学院 | 2023-01-24 | — | — | CN | claimed |
| CN-115626916-A | Pomalidomide derivative and preparation method and application thereof | 河南科技大学第一附属医院 | 2023-01-20 | — | — | CN | claimed |
| CN-115557936-A | Preparation method and application of pomalidomide derivative capable of being used as feed additive | 河南湾流生物科技有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-116836217-B | Preparation and application of PROTAC degradation agent | 中国医学科学院药用植物研究所 | 2026-05-19 | — | — | CN | disclosed |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12595318-B2 | — | — | 2026-04-07 | — | — | US | disclosed |
| EP-4713017-A1 | CHIMERIC MOLECULE | UCL Business Ltd (GB) | 2026-03-25 | — | — | EP | disclosed |
| CN-121574171-A | Difunctional protein degradation agent of direct targeting proteasome, preparation method and application thereof | 浙大城市学院 | 2026-02-27 | — | — | CN | disclosed |
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2026-02-05 | — | — | US | disclosed |
| US-20090234105-A1 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-17 | — | — | US | disclosed |
| US-7560588-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080188638-A1 | Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof | INTEZYNE TECHNOLOGIES (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2007112362-A2 | CONSTRUCTION OF A MULTIVALENT SCFV THROUGH ALKYNE-AZIDE 1,3-DIPOLAR CYCLOADDITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234105-A1 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | LIG3, LIG1, IGSF11 | MGMT 2675/4885ABCG2 3056/4885 |
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, PSMC1, PSME3 | MGMT 600/4885ABCG2 3874/4885 |
| US-20080188638-A1 | Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof | LNPEP, GNE, DNPEP | MGMT 96/4885ABCG2 2864/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | MGMT 920/4885ABCG2 553/4885 |
| US-12595318-B2 | — | ALG1, ALG8, FUCA1 | MGMT 2673/4885ABCG2 511/4885 |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SLC11A2, ARG1, COL2A1 | MGMT 957/4885ABCG2 3175/4885 |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | GNE, EPRS1, ALG1 | MGMT 1735/4885ABCG2 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.